Owned and operated by a cf veteran 
Short answer: Retatrutide acts on three hormone receptors—GLP-1, GIP and glucagon—to reduce hunger, help you feel full, improve blood-sugar regulation and increase energy use. In clinical trials, those combined effects produced substantial loss of body weight and body fat, along with improvements in several metabolic markers. Retatrutide is still investigational and is not approved by Health Canada for routine use.
Last medically reviewed for evidence and Canadian regulatory context: August 2026. This article is educational and does not replace medical advice.
For additional background on the compound’s three-receptor mechanism, see this retatrutide research overview.
What does retatrutide do to the body?
Retatrutide changes how the brain, pancreas, stomach, liver and fat tissue respond to signals involved in appetite and metabolism. It is a single investigational molecule that activates receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon. This is why researchers call it a triple receptor agonist.
- Brain: reduces hunger, food cravings and the drive to eat.
- Stomach and gut: supports earlier fullness and may slow digestion, especially after a dose.
- Pancreas: increases glucose-dependent insulin release, helping the body manage blood sugar after meals.
- Liver: changes glucose and fat metabolism through glucagon-receptor activity.
- Fat tissue and energy balance: promotes a sustained calorie deficit and may increase energy expenditure.
- Whole body: can reduce body weight, waist size and fat mass while improving some cardiometabolic risk markers.
The key distinction is that retatrutide does more than suppress appetite. Its glucagon component is designed to influence energy use and liver metabolism, while GLP-1 and GIP affect satiety, insulin and nutrient handling. The net effect observed in trials is reduced calorie intake plus broader metabolic change.
How retatrutide works: GLP-1, GIP and glucagon explained
1. GLP-1 receptor activity
GLP-1 signalling tells appetite centres in the brain that the body has eaten. It supports satiety, reduces food intake and stimulates insulin when blood glucose is elevated. It can also slow gastric emptying, although that effect may vary over time. These actions help explain both weight loss and common digestive side effects such as nausea or constipation.
2. GIP receptor activity
GIP is another incretin hormone released after eating. It supports glucose-dependent insulin secretion and may work with GLP-1 to improve appetite regulation and metabolic response. Retatrutide’s combined GLP-1/GIP action overlaps with tirzepatide, but retatrutide adds glucagon-receptor activity.
3. Glucagon receptor activity
Glucagon normally helps maintain available energy, including by signalling the liver. In a deliberately balanced triple agonist, glucagon-receptor activation may increase energy expenditure and fat oxidation. On its own, glucagon can raise blood sugar; retatrutide’s GLP-1 and GIP activity is intended to counterbalance that effect through glucose-dependent insulin signalling.
What happens to appetite and digestion?
Many participants in incretin-drug trials report less hunger, fewer cravings and smaller portions. Retatrutide can strengthen the feeling of fullness after eating, making a sustained calorie deficit easier to maintain. Because the same pathways affect the gut, nausea, diarrhea, vomiting and constipation are among the most frequently reported adverse effects. Symptoms have generally been most noticeable during dose escalation in clinical studies.
Reduced appetite can also make it harder to consume enough protein, fibre, fluids and micronutrients. Any future approved use would require individualized clinical guidance, particularly for older adults, people with gastrointestinal disease and anyone at risk of malnutrition.
How much weight can retatrutide cause people to lose?
In the peer-reviewed phase 2 obesity trial published in the New England Journal of Medicine, adults without diabetes receiving the 12 mg dose lost an average of 24.2% of starting body weight at 48 weeks, compared with 2.1% with placebo. Weight loss had not clearly plateaued at the end of that study.
Later phase 3 results have continued to evaluate retatrutide in larger and more varied populations. Trial results cannot predict an individual’s outcome, and comparisons with semaglutide or tirzepatide are unreliable unless the drugs are tested head-to-head in similar groups for the same duration.
Weight change depends on dose, duration, baseline health, adherence and the trial population. It is also important to distinguish percentage points from pounds: a 24% reduction equals about 24 kg for someone starting at 100 kg, but individual results vary widely.
Does retatrutide burn fat or muscle?
Retatrutide reduces total body weight primarily by reducing fat mass, but some lean mass can also be lost—as occurs with most substantial weight loss. A body-composition substudy found that the proportion of lean-mass loss was broadly consistent with other obesity treatments rather than showing selective muscle destruction.
Preserving muscle during major weight loss generally involves adequate protein, resistance exercise and clinician monitoring. People should not assume that a lower number on the scale represents only fat loss.
Effects on blood sugar, insulin and diabetes
By activating GLP-1 and GIP receptors, retatrutide increases insulin release when glucose is elevated. Clinical research in people with type 2 diabetes has shown reductions in A1C and body weight. The glucose-dependent mechanism means low blood sugar is not expected to be common when an incretin drug is used alone, but risk can rise when combined with insulin or a sulfonylurea.
Retatrutide should not be described as an approved diabetes treatment in Canada. Its benefits and risks are still being characterized through controlled trials.
Effects on the liver, cholesterol and blood pressure
Weight loss and changes in glucagon signalling may reduce liver fat and improve markers associated with metabolic dysfunction-associated steatotic liver disease (MASLD). Trials have also reported favourable changes in waist circumference, triglycerides, some cholesterol measures and blood pressure. These are promising cardiometabolic signals, but they do not prove that retatrutide prevents heart attacks, strokes or liver complications. Dedicated outcome studies are needed.
What does retatrutide feel like in the body?
There is no single experience. A person may notice less food noise, earlier fullness and reduced interest in large meals. Others may first notice nausea, bloating, fatigue, diarrhea or constipation. Some trial participants had an increased resting heart rate. The intensity and timing of effects vary by dose and individual biology, and online anecdotes are not a substitute for controlled safety data.
Retatrutide side effects and safety risks
The most common adverse effects reported in trials have been gastrointestinal and often mild to moderate:
- nausea
- diarrhea
- vomiting
- constipation
- reduced appetite
- abdominal discomfort
Other observed or class-related concerns include increased heart rate, gallbladder problems, pancreatitis, dehydration and kidney stress related to severe vomiting or diarrhea. Rapid weight loss can also contribute to gallstones and loss of lean tissue. Long-term safety is not yet fully established.
Because retatrutide is investigational, contraindications and warnings for a final Canadian product label do not yet exist. It is especially important not to copy prescribing instructions from approved GLP-1 drugs and present them as established retatrutide guidance.
Is retatrutide approved in Canada?
No. As of August 2026, retatrutide is not approved by Health Canada for weight loss, diabetes or any other routine medical use. It is being studied in clinical trials, including Canadian research sites. You can verify authorized studies in Health Canada’s Clinical Trials Database and review the developer’s current overview on Eli Lilly’s retatrutide information page.
Products sold online as retatrutide are not the same as a Health Canada-authorized prescription medicine. Identity, strength, sterility and contaminants may be unknown. Red Leaf Research Labs’ retatrutide reference material is presented for laboratory research context and is not a therapeutic recommendation.
Retatrutide vs. Ozempic, Wegovy and Mounjaro
| Drug | Receptors targeted | Canadian status |
|---|---|---|
| Retatrutide | GLP-1 + GIP + glucagon | Investigational; not approved |
| Semaglutide (Ozempic/Wegovy) | GLP-1 | Approved products with specific indications |
| Tirzepatide (Mounjaro/Zepbound) | GLP-1 + GIP | Approved products with specific indications |
Retatrutide adds glucagon-receptor activity, which may help explain its effects on energy expenditure and liver metabolism. However, percentages from separate trials should not be treated as a direct ranking of effectiveness. Study length, participant characteristics and analysis methods differ.
Frequently asked questions about what retatrutide does to the body
What organs does retatrutide affect?
Retatrutide’s hormone-receptor activity affects appetite centres in the brain, insulin signalling in the pancreas, digestion in the stomach and gut, and glucose and fat metabolism in the liver. Its whole-body energy effects also influence fat and lean tissue.
Does retatrutide speed up metabolism?
It may increase energy expenditure through glucagon-receptor activity, while also reducing calorie intake through GLP-1 and GIP pathways. “Speeding up metabolism” is an oversimplification; the observed weight loss reflects several coordinated mechanisms.
Does retatrutide get rid of belly fat?
Trials have shown reductions in total weight and waist circumference, which indicates loss of abdominal fat for many participants. It cannot target fat from one specific body area, and individual fat-loss patterns vary.
How quickly does retatrutide work?
Appetite or digestive effects may appear earlier, but meaningful body-weight changes build over months. In trials, doses were gradually escalated and outcomes were measured over many months. There is no validated do-it-yourself timeline.
Does retatrutide reduce food noise?
Its appetite pathways can reduce hunger and preoccupation with food for some people. “Food noise” is an informal description, not a standardized clinical endpoint, so experiences differ.
Does retatrutide make you tired?
Fatigue has been reported by some trial participants. It may also relate to eating less, dehydration, gastrointestinal symptoms or another health issue. Persistent or severe fatigue requires medical assessment.
Can retatrutide cause hair loss?
Hair shedding can occur after rapid weight loss or inadequate nutrition, regardless of the method used. Current evidence does not establish hair loss as a unique direct action of retatrutide.
Does retatrutide cause muscle loss?
Some lean mass can be lost during substantial weight reduction, but available body-composition evidence suggests most weight lost is fat mass. Protein intake, resistance training and clinical monitoring may help preserve muscle.
Can retatrutide lower blood sugar too much?
Its insulin effect is glucose-dependent, so hypoglycemia is less likely when used alone. Risk may be higher with insulin or insulin-releasing medicines. Because it is not approved, there is no Canadian prescribing protocol for routine use.
Does retatrutide affect the heart?
Trials have reported improvements in several cardiovascular risk markers alongside a dose-related increase in heart rate in some participants. Whether it reduces major cardiovascular events is being studied and should not be assumed.
What happens when someone stops retatrutide?
Long-term discontinuation data are still developing. With other incretin-based obesity medicines, appetite and weight commonly rise after treatment stops. Retatrutide-specific maintenance studies are examining this question.
Is retatrutide the same as Ozempic?
No. Ozempic contains semaglutide and targets GLP-1 receptors. Retatrutide targets GLP-1, GIP and glucagon receptors and remains investigational.
Is retatrutide stronger than tirzepatide?
Retatrutide produced very large average weight reductions in its trials, but “stronger” cannot be concluded from separate studies. A properly designed head-to-head trial would be needed for a fair comparison.
Can you get retatrutide by prescription in Canada?
Not as a routine prescription. It is not Health Canada-approved. Legitimate access is limited to eligible participants in authorized clinical trials.
Is online “research retatrutide” safe to inject?
No online research product should be assumed safe, sterile or suitable for human use. A label or certificate does not make an unapproved product a Health Canada-authorized medicine.
The bottom line
What retatrutide does to the body is best understood as a three-part metabolic effect: it reduces hunger through GLP-1 and GIP signalling, supports glucose-dependent insulin responses, and adds glucagon-receptor activity that may increase energy expenditure and alter liver metabolism. The result in clinical trials has been substantial weight and fat loss with improvements in several metabolic measures—but also frequent gastrointestinal side effects and unresolved long-term safety questions.
For Canadians, the most important fact is simple: retatrutide remains an investigational drug, not a Health Canada-approved treatment. Follow official trial and regulatory sources rather than dosing advice or product claims found online.
